Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma

Suzanne Trudel, MSc, MD, associate professor, University of Toronto; clinician scientist, Princess Margaret Cancer Centre, discusses primary results and subgroup analyses from the phase 3 DREAMM-7 trial (NCT04246047) of belantamab mafodotin (Blenrep), bortezomib (Velcade), and dexamethasone (BVd) vs daratumumab (Darzalex), bortezomib and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma.